摘要
孕酮受体膜组分1和2,neudesin和neuferricin均属于膜孕激素受体(MAPR)家庭。最近,性类固醇膜受体因为潜在参与了性激素介导的快速非基因组的效应已获得了关注,目前尚不能解释核受体的基因组作用。孕酮可能通过包括丝裂原活化蛋白激酶的活化(MAPK)以及通过MAPRs的磷脂酰肌醇3激酶(PI3K)通路的非基因组效应来增加细胞的增殖和存活。此外,MAPRs独特的表达表明它们可能被用来作为生物标志物以及与性激素有关的癌症和其他疾病的药物靶点。在这篇综述中,我们总结了MAPRs的生理作用,提供一个全面的概述,关于他们的孕激素介导的非基因组作用的新见解,并讨论了其潜在的治疗靶点。
关键词: 孕酮;PGRMC1; PGRMC2;neudesin;neuferricin;癌症。
Current Drug Targets
Title:Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Volume: 17 Issue: 10
Author(s): Sae Hasegawa, Mayu Kasubuchi, Kazuya Terasawa, Ikuo Kimura
Affiliation:
关键词: 孕酮;PGRMC1; PGRMC2;neudesin;neuferricin;癌症。
摘要: Progesterone receptor membrane components 1 and 2, neudesin, and neuferricin belong to the membraneassociated progesterone receptor (MAPR) family. Recently, sex steroid membrane receptors have gained attention because of their potential involvement in sex hormone-mediated rapid non-genomic effects, which cannot currently be explained by the genomic action of nuclear receptors. Progesterone may increase cell proliferation and survival via nongenomic effects including the activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3- kinase (PI3K) pathways through MAPRs. Moreover, the unique expression of MAPRs suggests that they could be used as biomarkers and drug targets for sex steroid-related cancers and other diseases. In this review, we summarize the physiological roles of the MAPRs, provide a comprehensive overview of their progesterone-mediated non-genomic actions, and discuss new insights into their potential as therapeutic targets.
Export Options
About this article
Cite this article as:
Sae Hasegawa, Mayu Kasubuchi, Kazuya Terasawa, Ikuo Kimura , Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450116666150518102651
DOI https://dx.doi.org/10.2174/1389450116666150518102651 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
Current Pharmaceutical Design Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies
Mini-Reviews in Medicinal Chemistry Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Microbial Metabolomics
Current Genomics Proteins as Alternate Targets of Enediynes
Letters in Drug Design & Discovery Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins
Current Drug Targets